Income statement
USD
Annual
| Metric | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | -136K | 0 | 0 | 0 |
| Operating Income | -6M | -903K | -228K | -193K |
| EBITDA | -17M | -903K | -356K | -256K |
| Net Income | -17M | -907K | -266K | -193K |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$0.00001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 8, 2026
Coverage: 241 bars · Jun 23, 2025 → Jun 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pure Global Cannabis Inc. (PRCNF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 8, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -905.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -905.9%, free cash flow -4911.8% with operating margin 0.0% and ROIC -34.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PRCNF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRCNF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRCNF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRCNF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$192.6K
+27.5% YoY
Free Cash Flow
-$62.4K
-62.6% YoY
Revenue Growth
+0.0%
EPS Growth
-905.9%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | -136K | 0 | 0 | 0 |
| Operating Income | -6M | -903K | -228K | -193K |
| EBITDA | -17M | -903K | -356K | -256K |
| Net Income | -17M | -907K | -266K | -193K |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|
| Cash & Equivalents | 6M | 15K | 100 | 16K |
| Total Assets | 16M | 26K | 20K | 37K |
| Total Liabilities | 10M | 370K | 548K | 303K |
| Shareholder Equity | 7M | -344K | -529K | -266K |
| Total Debt | 9M | 0 | 0 | 0 |
| Net Debt | 3M | -15K | -100 | -16K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
55K
-239.8% YoY
Capital Expenditures
8K
+65.0% YoY
Free Cash Flow
62K
-62.6% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-539.3%
Debt / Equity
1.33x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.